Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 4
2010 1
2011 1
2012 1
2013 5
2014 8
2015 6
2016 16
2017 9
2018 13
2019 21
2020 20
2021 22
2022 18
2023 12
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Page 1
Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Bui TO, Dao VT, Nguyen VT, Feugeas JP, Pamoukdjian F, Bousquet G. Bui TO, et al. Eur Urol. 2022 Apr;81(4):349-361. doi: 10.1016/j.eururo.2021.12.010. Epub 2022 Jan 3. Eur Urol. 2022. PMID: 34991918 Review.
CONTEXT: Although antiangiogenic treatments and immunotherapies have significantly improved the prognosis of metastatic renal cell carcinoma (RCC), many patients will develop resistance, leading to treatment failure. ...
CONTEXT: Although antiangiogenic treatments and immunotherapies have significantly improved the prognosis of metastatic renal …
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. Aldin A, et al. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. Cochrane Database Syst Rev. 2023. PMID: 37146227 Review.
Where possible, analyses were conducted for the different risk groups (favourable, intermediate, poor) according to the International Metastatic Renal-Cell Carcinoma Database Consortium Score (IMDC) or the Memorial Sloan Kettering Cancer Center (MSKCC) …
Where possible, analyses were conducted for the different risk groups (favourable, intermediate, poor) according to the International Met …
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Rathmell WK, et al. J Clin Oncol. 2022 Sep 1;40(25):2957-2995. doi: 10.1200/JCO.22.00868. Epub 2022 Jun 21. J Clin Oncol. 2022. PMID: 35728020
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
Lombardi P, Filetti M, Falcone R, Di Bidino R, Iacovelli R, Ciccarese C, Bria E, Tortora G, Scambia G, Daniele G. Lombardi P, et al. Cancer Treat Rev. 2022 May;106:102377. doi: 10.1016/j.ctrv.2022.102377. Epub 2022 Mar 16. Cancer Treat Rev. 2022. PMID: 35313232 Review.
Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied in metastatic renal cell carcinoma (mRCC) without any direct comparison between the regimens. ...
Several first-line immune-checkpoints inhibitors (ICI) based combinations have been studied in metastatic renal cell …
Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Unverzagt S, et al. Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2. Cochrane Database Syst Rev. 2017. PMID: 28504837 Free PMC article. Review.
BACKGROUND: Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm shift from non-specific therapy with broad-acting cytokines to specific regimens, which directly target the cancer, the tumour microenvironm …
BACKGROUND: Since the mid-2000s, the field of metastatic renal cell carcinoma (mRCC) has experienced a paradigm …
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
Chen B, Li J, Huang Y, Tang B, Jiang J, Chen Z, Li J, Wang P, Cao D, Liu L, Wei Q. Chen B, et al. Int J Surg. 2023 Apr 1;109(4):982-994. doi: 10.1097/JS9.0000000000000314. Int J Surg. 2023. PMID: 36974696 Free PMC article.
BACKGROUND: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial. In addition, several unanswered questions regarding the use of CN remain: Can CN provide survival benefits for patients with mRCC? . …
BACKGROUND: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controv …
Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.
Feng YN, Xie GY, Xiao L, Mo DC, Huang JF, Luo PH, Liang XJ. Feng YN, et al. Front Immunol. 2023 Jun 19;14:1196793. doi: 10.3389/fimmu.2023.1196793. eCollection 2023. Front Immunol. 2023. PMID: 37404816 Free PMC article.
INTRODUCTION: Immune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse …
INTRODUCTION: Immune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal …
Metastatic tumors to the pancreas: a systematic review and meta-analysis.
Sperti C, Pozza G, Brazzale AR, Buratin A, Moletta L, Beltrame V, Valmasoni M. Sperti C, et al. Minerva Chir. 2016 Oct;71(5):337-44. Epub 2016 Jul 14. Minerva Chir. 2016. PMID: 27412234 Review.
Pancreatic resection for renal cell cancer showed better survival compared to other non-renal cell cancer (ratio of mean 1.83; 95% CI: 1.42-2.36, I2=74.52%, P<0.001). Disease-free interval was longer for metastatic renal cell carcinoma patients (mea …
Pancreatic resection for renal cell cancer showed better survival compared to other non-renal cell cancer (ratio of mean 1.83; 95% CI: 1.42- …
Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis.
Li KP, He M, Wan S, Chen SY, Wang CY, Li XR, Yang L. Li KP, et al. Int J Surg. 2023 Oct 1;109(10):3178-3188. doi: 10.1097/JS9.0000000000000591. Int J Surg. 2023. PMID: 37462997 Free PMC article.
BACKGROUND: This study aimed to conduct a pooled analysis to compare the outcomes of patients with metastatic renal cell carcinoma who received presurgical systemic therapy [(ST); including immunotherapy and/or targeted therapy] followed by cytoreducti …
BACKGROUND: This study aimed to conduct a pooled analysis to compare the outcomes of patients with metastatic renal cell …
Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Buti S, et al. Anticancer Drugs. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1. Anticancer Drugs. 2013. PMID: 23552469 Review.
The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved markedly with targeted therapies. ...
The prognosis of patients affected by metastatic renal cell carcinoma (mRCC) has improved markedly with targeted …
135 results